Manish Kumar Saraf

Manish Kumar Saraf

Manish Kumar Saraf
Biochemistry & Molecular Biology
University of Texas Medical Branch, USA


Manish Kumar Saraf is a Research Scientist I in Department of Surgery and Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, Texas. He earned a PhD degree from Department of
Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India and received M.Pharm (Master of Pharmacy) degree in Pharmacology from Department of Pharmaceutical Science and Drug Research, Punjabi University, Patiala, India and B.Pharm (Bachelor of Pharmacy) degree from Department of Pharmaceutical Science, Dr. H. S. Gour, University, Sagar, India.  He got a post doc experience from Internal Medicine, UTMB, Galveston and from Neuropharmacology, University of Pompeu Fabara, Barcelona. He has 8 years of pre-doc and more than 4 years of post-doc research experience. He received multiple travel awards from international and national organization (IBRO, SfN, DST, INSA). He has published over 11 research articles in peered reviewed journals and presented his research work in various international and national conferences and scientific meetings (19). He has reviewed many research articles of various reputed journals. He is a member of various scientific societies (Endocrine Society, American Association of Society for Neuroscience, International Brain Research Organization, Indian Pharmacological Society, Neurology Society of India, Indian Science Congress Association, PGI Neurological Society, Indian Academy of Neuroscience.

Research Interest

Severe burn injury produces an overwhelming hypermetabolic stress response affecting all major organs and systems in the body. Elevated level of catecholamine is the important mediators of hypermetabolic response
observed in severe burn injury. Currently, he is involved in studying the expression of the adipose tissue lipolytic enzymes and lipid droplet-associated proteins in healthy children and adolescents. He is also
currently  working on a hypothesis is that Propranolol (non-selective beta-adrenoceptor antagonist) will attenuate the hypermetabolic response, leading to short-term (during acute hospitalization) and long-term (one
year post-burn) improvements in lipid and protein metabolism.